Indication
Alzheimer’s Disease
Rivastigmine is indicated for the treatment of mild-to-moderate dementia of the Alzheimer's type (AD).
Parkinson’s Disease Dementia
Rivastigmine is indicated for the treatment of mild-to-moderate dementia associated with Parkinson’s disease (PD).
Dosage & Administration
Rivastigmine should be taken with meals in divided doses in the morning and evening.
Initial Dose: Initiate treatment with the 1.5 mg twice a day with Rivastigmine.
Dose Titration: After a minimum of 2 weeks and if well tolerated, increase the dose to 3 mg twice a day. Subsequent increases to 4.5 mg twice a day and 6 mg twice a day should be attempted after a minimum of 2 weeks at the previous dose and if well tolerated. The maximum dose is 6 mg twice a day (12 mg per day).
Dosing in specific populations
Renal Impairment
Patients with moderate and severe renal impairment may be able to only tolerate lower doses.
Hepatic Impairment
Patients with mild and moderate hepatic impairment may be able to only tolerate lower doses. No data are available on the use of Rivastigmine in patients with severe hepatic impairment.
Low Body Weight
Carefully titrate and monitor patients with low body weight (less than 50 kg) for toxicities (e.g., excessive nausea, vomiting), and consider reducing the dose if such toxicities develop.
Pregnancy and Lactation
Rivastigmine is classified as pregnancy category B, with insufficient data on risks associated with breastfeeding. Rivastigmine should be used during pregnancy or lactation only if the potential benefit justifies the potential risk to the fetus.
Usage in pediatric patient
Safety and effectiveness in pediatric patients have not been established. The use of Rivastigmine in pediatric patients (below 18 years of age) is not recommended.
Precautions
